Title:
NALIDINONE COMPOUND AS FGFR4 INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/060904
Kind Code:
A1
Abstract:
Disclosed is a 2-oxo-1,2-dihydro-1,6-naphthyridin-7-yl compound, which is a compound having a structure as shown in formula (I), a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof; R1 is selected from one or more of a halogen or a C1-C6 alkoxy group; R2 is -(CH2)nNR3R4 or -(CH2)nOH, n being 2 or 3; R3 and R4 are independently selected from alkyl groups, or R3 and R4 are combined with an N atom connecting R3 and R4 to form a 5-6 membered ring group. The compound can selectively inhibit FGFR4, and can be used as a potential antitumor drug.
More Like This:
Inventors:
LI XIAOKUN (CN)
LIU ZHIGUO (CN)
ZHEN XIAOHUI (CN)
LIN LI (CN)
QIAN JIANCHANG (CN)
LIU ZHIGUO (CN)
ZHEN XIAOHUI (CN)
LIN LI (CN)
QIAN JIANCHANG (CN)
Application Number:
PCT/CN2022/095973
Publication Date:
April 20, 2023
Filing Date:
May 30, 2022
Export Citation:
Assignee:
UNIV WENZHOU MEDICAL (CN)
International Classes:
C07D471/04; A61P35/00
Domestic Patent References:
WO2018113584A1 | 2018-06-28 |
Foreign References:
CN113912602A | 2022-01-11 | |||
CN109745325A | 2019-05-14 | |||
CN108264511A | 2018-07-10 | |||
CN105307657A | 2016-02-03 | |||
CN109384790A | 2019-02-26 | |||
CN104540809A | 2015-04-22 |
Attorney, Agent or Firm:
HANGZHOU ZHIXIAN PATENT AGENCY (CN)
Download PDF: